1. Home
  2. AVDL

as of 12-05-2025 3:59pm EST

$21.34
$0.02
-0.07%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Chart Type:
Time Range:
Founded: 2015 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 2
Market Cap: 2.1B IPO Year: 1996
Target Price: $18.38 AVG Volume (30 days): 2.8M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.00 EPS Growth: N/A
52 Week Low/High: $6.38 - $23.57 Next Earning Date: 11-04-2025
Revenue: $248,517,000 Revenue Growth: 79.88%
Revenue Growth (this year): 65.47% Revenue Growth (next year): 30.88%

AI-Powered AVDL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 72.60%
72.60%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Avadel Pharmaceuticals plc News

AVDL Breaking Stock News: Dive into AVDL Ticker-Specific Updates for Smart Investing

All AVDL News

Share on Social Networks: